Bicocca Open Archive

Logo unimib boa
COLOMBO, NICOLETTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 41.095
AS - Asia 25.556
EU - Europa 15.487
SA - Sud America 3.806
Continente sconosciuto - Info sul continente non disponibili 1.465
AF - Africa 513
OC - Oceania 73
AN - Antartide 1
Totale 87.996
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 38.796
SG - Singapore 8.341
IT - Italia 5.513
CN - Cina 4.687
VN - Vietnam 4.089
HK - Hong Kong 3.813
BR - Brasile 2.879
RU - Federazione Russa 2.582
CA - Canada 1.834
BD - Bangladesh 1.686
IE - Irlanda 1.395
UA - Ucraina 1.088
SE - Svezia 994
DE - Germania 917
GB - Regno Unito 738
FR - Francia 653
IN - India 538
FI - Finlandia 487
KR - Corea 432
ID - Indonesia 393
AR - Argentina 355
AT - Austria 287
JP - Giappone 245
NL - Olanda 233
TR - Turchia 214
IQ - Iraq 192
ZA - Sudafrica 167
MX - Messico 165
EC - Ecuador 155
PK - Pakistan 138
ES - Italia 114
SA - Arabia Saudita 113
CO - Colombia 107
PH - Filippine 98
VE - Venezuela 92
UZ - Uzbekistan 82
MA - Marocco 81
PY - Paraguay 67
DK - Danimarca 64
TW - Taiwan 62
CL - Cile 61
AU - Australia 60
CR - Costa Rica 59
JM - Giamaica 59
MY - Malesia 59
KE - Kenya 57
EG - Egitto 53
PL - Polonia 52
CH - Svizzera 46
TH - Thailandia 40
RO - Romania 38
NP - Nepal 36
JO - Giordania 35
BE - Belgio 34
TN - Tunisia 34
PE - Perù 33
AE - Emirati Arabi Uniti 32
DZ - Algeria 32
NI - Nicaragua 32
HN - Honduras 27
IR - Iran 27
AZ - Azerbaigian 26
BG - Bulgaria 26
TT - Trinidad e Tobago 26
UY - Uruguay 26
BO - Bolivia 24
CZ - Repubblica Ceca 24
GT - Guatemala 23
IL - Israele 22
LT - Lituania 22
ET - Etiopia 21
LB - Libano 21
OM - Oman 21
RS - Serbia 21
EU - Europa 20
PT - Portogallo 20
GR - Grecia 18
KZ - Kazakistan 18
AL - Albania 17
NO - Norvegia 17
SN - Senegal 16
PS - Palestinian Territory 13
SV - El Salvador 13
HR - Croazia 12
HU - Ungheria 12
QA - Qatar 12
DO - Repubblica Dominicana 11
SY - Repubblica araba siriana 11
BB - Barbados 10
EE - Estonia 10
KG - Kirghizistan 10
MD - Moldavia 9
NZ - Nuova Zelanda 9
PA - Panama 9
AO - Angola 8
BY - Bielorussia 8
GE - Georgia 8
A2 - ???statistics.table.value.countryCode.A2??? 7
BA - Bosnia-Erzegovina 6
CI - Costa d'Avorio 6
Totale 86.405
Salva come PNG Salva come JPEG
Città #
Singapore 4.407
Hong Kong 3.754
Ashburn 3.393
Ann Arbor 3.338
Woodbridge 2.686
Fairfield 2.358
San Jose 2.158
Houston 1.942
Milan 1.630
Dublin 1.310
Toronto 1.293
Ho Chi Minh City 1.236
Jacksonville 1.216
New York 1.070
Wilmington 1.035
Seattle 946
Hanoi 945
Hefei 867
Council Bluffs 854
Chicago 833
Cambridge 788
Santa Clara 778
Dearborn 738
Chandler 697
The Dalles 659
Princeton 642
Rome 577
Los Angeles 553
Dallas 499
Beijing 440
Lauterbourg 406
Seoul 389
Frankfurt am Main 375
Lawrence 315
Moscow 310
Altamura 290
Buffalo 289
Nanjing 285
Jakarta 258
São Paulo 237
Helsinki 215
Vienna 207
Lachine 202
Figino 199
Boardman 187
Guangzhou 185
Shanghai 167
Haiphong 163
San Diego 149
Da Nang 148
Nuremberg 148
Phoenix 143
Tokyo 137
London 130
Naples 128
Andover 125
Turin 120
Columbus 97
Dong Ket 96
Rio de Janeiro 92
Nanchang 89
Biên Hòa 86
Salt Lake City 85
Atlanta 80
Tashkent 77
Tianjin 77
Shenyang 76
Hamburg 75
Changsha 74
Miami 72
Falls Church 70
Dhaka 68
Boston 63
Orem 63
Philadelphia 63
Ottawa 62
Quận Bình Thạnh 62
Ha Long 61
Hải Dương 61
Hebei 60
Johannesburg 60
Brooklyn 58
Tampa 58
Washington 58
Montreal 57
Newark 57
Ninh Bình 57
Baghdad 56
San Francisco 56
Norwalk 55
Brasília 53
Guayaquil 53
Can Tho 52
Hangzhou 52
Denver 51
Lahore 51
Quito 50
Thái Nguyên 50
Mountain View 49
Riyadh 49
Totale 52.340
Salva come PNG Salva come JPEG
Nome #
ESGO–ESTRO–ESP guidelines for the management of patients with endometrial carcinoma: update 2025 685
Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA -Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial 637
ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up 626
High-dose epirubicin in patients with advanced or recurrent uterine sarcoma 593
Early CAR- CD4+ T-lymphocytes recovery following CAR-T cell infusion: A worse outcome in diffuse large B cell lymphoma 435
Erratum: Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (Annals of Oncology (2017) 28 (iv72-iv83) DOI: 10.1093/annonc/mdx220) 405
ESMO-ESGO consensus conference recommendations on ovarian cancer: Pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease 405
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer 404
Early-stage clear cell ovarian cancer compared to high-grade histological subtypes: An outcome exploratory analysis in two oncology centers 386
Long-term results of fertility-sparing treatment compared with standard radical surgery for early-stage epithelial ovarian cancer 373
Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer 370
Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer 368
Harmonising clinical trials within the Gynecologic Cancer InterGroup: Consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference 366
Randomized phase III clinical trial evaluating weekly cisplatin for advanced epithelial ovarian cancer 351
CD73 Regulates Stemness and Epithelial-Mesenchymal Transition in Ovarian Cancer-Initiating Cells 347
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial 337
Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study 331
FORWARD I: A Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer 324
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study 321
Pembrolizumab or Placebo With Chemoradiotherapy Followed by Pembrolizumab or Placebo for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): Overall Survival Results From a Randomized, Double-blind, Placebo-Controlled, Phase 3 Trial 316
Conservative management of early-stage epithelial ovarian cancer: results of a large retrospective series 314
ESMO-ESGO consensus conference recommendations on ovarian cancer: Pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease 301
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer 298
Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer 295
Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomised trial 293
Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer 293
Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study 290
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial 282
Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnostics 282
Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 281
Pre-operative evaluation of epithelial ovarian cancer patients: Role of whole body diffusion weighted imaging MR and CT scans in the selection of patients suitable for primary debulking surgery. A single-centre study 280
Mirvetuximab soravtansine in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer: Final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial 277
Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial 276
Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: A phase III trial of the AGO OVAR, COGI, GINECO, and GEICO-the MIMOSA study 271
Ultrasonographic diagnosis and longitudinal follow-up of recurrences after conservative surgery for borderline ovarian tumors 271
The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale 270
Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation 268
The disposition of carboplatin in ovarian cancer patients 265
ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer 265
Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12 262
Long-term follow-up of patients with an isolated ovarian recurrence after conservative treatment of epithelial ovarian cancer: review of the results of an international multicenter study comprising 545 patients 260
Robotic Versus Open Radical Hysterectomy in Women With Locally Advanced Cervical Cancer After Neoadjuvant Chemotherapy: A Single-institution Experience of Surgical and Oncologic Outcomes 259
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): A randomised, double-blind, placebo-controlled, phase 3 trial 259
Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial 257
Neoadjuvant chemotherapy in cervical cancer: An update 256
Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial 253
Effect of a streptococcal preparation (OK432) on natural killer activity of tumour-associated lymphoid cells in human ovarian carcinoma and on lysis of fresh ovarian tumour cells 252
A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis 250
Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer 249
Clinical benefit and risk of death with endocrine therapy in ovarian cancer: A comprehensive review and meta-analysis 248
Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer 248
Sentinel lymph node biopsy in pregnant patients with breast cancer 245
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial 245
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: A phase III trial of the gynecologic cancer intergroup 244
A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups 244
Peripheral neurotoxicity of taxol in patients previously treated with cisplatin 242
Hydrological, thermal and chemical influence of an intact rock glacier discharge on mountain stream water 241
Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results 241
Comparing Outcomes Between CPX-351 and Fludarabine-Based Induction in Secondary Acute Myeloid Leukemia in the Real-World Setting: The Prognostic Role of Measurable Residual Disease 240
Diffusion-weighted MR imaging in assessing cervical tumour response to nonsurgical therapy 240
A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites 239
Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study 239
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial 239
Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer 238
A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial 237
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up 236
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval 233
Hexamethylmelamine, adriamycin, and cyclophosphamide (HAC) versus cis-dichlorodiamineplatinum, adriamycin, and cyclophosphamide (PAC) in advanced ovarian cancer: a randomized clinical trial 233
Neoadjuvant chemotherapy prior to pelvic exenteration in patients with recurrent cervical cancer: Single institution experience 233
Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale 232
Surgical management of malignant ovarian germ-cell tumors: 10 years' experience of 129 patients 232
Platinum-based neoadjuvant chemotherapy followed by radical surgery for cervical carcinoma international federation of gynecology and obstetrics stage IB2-IIB 232
Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial 232
Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 231
Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients 231
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma 231
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: A randomised phase 2 trial 231
A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative Study 231
Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study 230
Early oral versus "traditional" postoperative feeding in gynecologic oncology patients undergoing intestinal resection: A randomized controlled trial 230
Outcome according to residual disease (surgeon's report vs pre-chemotherapy imaging) in patients with bevacizumab-treated ovarian cancer: Analysis of the ROSiA study 230
Robotic Surgery: Changing the Surgical Approach for Endometrial Cancer in a Referral Cancer Center 229
The role of surgery in gestational trophoblastic disease 229
Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives 229
An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens 228
Reply to M.L. Friedlander et al 227
Risk-reducing salpingo-oophorectomy in women at higher risk of ovarian and breast cancer: A single institution prospective series 227
Chemo-conization in early cervical cancer 226
Defective natural killer activity within human ovarian tumors: Low numbers of morphologically defined effectors present in situ 226
Trabectedin as single agent in relapsed advanced ovarian cancer: Results from a retrospective pooled analysis of three phase II trials 226
Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status 226
Lack of activity of cyclophosphamide in ovarian cancer patients refractory to cis-dichlorodiammine platinum 225
A reassessment of the role of second-look laparotomy in advanced ovarian cancer 224
Low-dose oral etoposide in epithelial cancer of the ovary 224
Analysis of gene expression identifies PLAB as a mediator of the apoptotic activity of fenretinide in human ovarian cancer cells 223
Experience with trabectedin + pegylated liposomal doxorubicin for recurrent platinum-sensitive ovarian cancer unsuited to platinum rechallenge 223
Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients 223
External validation of the Annual Recurrence Risk Model (ARRM) for tailored surveillance strategy in patients with cervical cancer 223
GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of treatment in patients with recurrent low grade serous ovarian cancer 222
BRCA1/2 molecular assay for ovarian cancer patients: A survey through Italian departments of oncology and molecular and genomic diagnostic laboratories 222
Totale 28.169
Salva come PNG Salva come JPEG
Categoria #
all - tutte 288.527
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 288.527
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.228 0 0 0 237 184 196 168 209 186 250 231 567
2022/20234.033 665 1.028 274 226 247 729 59 327 243 66 95 74
2023/20244.164 98 105 176 111 637 1.033 755 107 525 117 68 432
2024/202513.024 713 1.688 492 616 1.039 526 998 405 1.286 1.616 1.088 2.557
2025/202634.535 3.666 3.062 2.373 3.235 2.689 1.547 3.834 1.853 2.529 2.559 3.118 4.070
2026/20279.407 2.173 2.255 4.341 638 0 0 0 0 0 0 0 0
Totale 87.996